Reduction of stroke incidence after myocardial infarction with pravastatin: the Cholesterol and Recurrent Events (CARE) study. The Care Investigators.

BACKGROUND The role of lipid modification in stroke prevention is controversial, although increasing evidence suggests that HMG-CoA reductase inhibition may reduce cerebrovascular events in patients with prevalent coronary artery disease. METHODS AND RESULTS To test the hypothesis that cholesterol reduction with pravastatin may reduce stroke incidence after myocardial infarction, we followed 4159 subjects with average total and LDL serum cholesterol levels (mean, 209 and 139 mg/dL, respectively) who had sustained an infarction an average of 10 months before study entry and who were randomized to pravastatin 40 mg/d or placebo in the Cholesterol and Recurrent Events (CARE) trial. Using prospectively defined criteria, we assessed the incidence of stroke, a prespecified secondary end point, and transient ischemic attack (TIA) over a median 5-year follow-up period. Patients were well matched for stroke risk factors and the use of antiplatelet agents (85% of subjects in each group). Compared with placebo, pravastatin lowered total serum cholesterol by 20%, LDL cholesterol by 32%, and triglycerides by 14% and raised HDL cholesterol by 5% over the course of the trial. A total of 128 strokes (52 on pravastatin, 76 on placebo) and 216 strokes or TIAs (92 on pravastatin, 124 on placebo) were observed, representing a 32% reduction (95% CI, 4% to 52%, P=0.03) in all-cause stroke and 27% reduction in stroke or TIA (95% CI, 4% to 44%, P=0.02). All categories of strokes were reduced, and treatment effect was similar when adjusted for age, sex, history of hypertension, cigarette smoking, diabetes, left ventricular ejection fraction, and baseline total, HDL, and LDL cholesterol and triglyceride levels. There was no increase in hemorrhagic stroke in patients on pravastatin compared with placebo (2 versus 6, respectively). CONCLUSIONS Pravastatin significantly reduced stroke and stroke or TIA incidence after myocardial infarction in patients with average serum cholesterol levels despite the high concurrent use of antiplatelet therapy.

[1]  Scandinavian Simvastatin Survival Study Group.  Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S) , 1995, The Lancet.

[2]  J. Massé.  Effect of lovastatin on early carotid atherosclerosis. , 1995, Circulation.

[3]  C. Date,et al.  Risk factors for cerebral hemorrhage and cerebral infarction in a Japanese rural community. , 1982, Stroke.

[4]  C. Furberg,et al.  Relation between blood lipids, lipoproteins, and cerebrovascular atherosclerosis. A review. , 1988, Stroke.

[5]  C. Furberg,et al.  Reductase inhibitor monotherapy and stroke prevention. , 1997, Archives of internal medicine.

[6]  D. Jacobs,et al.  Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial. , 1989, The New England journal of medicine.

[7]  J. Bogousslavsky,et al.  Mechanism of late stroke after myocardial infarct: the Lausanne Stroke Registry. , 1993, Journal of neurology, neurosurgery, and psychiatry.

[8]  A. Nissinen,et al.  Twenty-year stroke mortality and prediction in twelve cohorts of the Seven Countries Study. , 1990, International journal of epidemiology.

[9]  D. Reed,et al.  Serum cholesterol and hemorrhagic stroke in the Honolulu Heart Program. , 1989, Stroke.

[10]  HOMAS,et al.  The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol Levels , 2000 .

[11]  S. Duffy,et al.  Lipids Are Risk Factors for Ischaemic Stroke: Overview and Review , 1992 .

[12]  J. Popper,et al.  Factors Related to Stroke Incidence in Hawaii Japanese Men: The Honolulu Heart Study , 1980, Stroke.

[13]  C. Furberg,et al.  Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries (PLAC-II) , 1995, The American journal of cardiology.

[14]  J. Salonen,et al.  Kuopio Atherosclerosis Prevention Study (KAPS). A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries. , 1995, Circulation.

[15]  J. Salonen,et al.  Relation of blood pressure, serum lipids, and smoking to the risk of cerebral stroke. A longitudinal study in Eastern Finland. , 1982, Stroke.

[16]  Ames,et al.  PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA , 2000 .

[17]  G. Lamas,et al.  Ventricular dysfunction and the risk of stroke after myocardial infarction. , 1997, The New England journal of medicine.

[18]  J. Stamler.  Clofibrate and niacin in coronary heart disease. , 1975, JAMA.

[19]  Scandinavian Simvastatin Survival Study Group.  Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) , 1994, The Lancet.

[20]  C. Furberg,et al.  Reduction in cardiovascular events during pravastatin therapy. Pooled analysis of clinical events of the Pravastatin Atherosclerosis Intervention Program. , 1995, Circulation.

[21]  J. Stengård,et al.  Antibodies to glutamic acid decarboxylase as predictors of insulin-dependent diabetes mellitus before clinical onset of disease , 1994, The Lancet.

[22]  N. Delanty,et al.  Vascular effects of statins in stroke. , 1997, Stroke.

[23]  P. Allhoff,et al.  The Honolulu Heart Program , 1991 .

[24]  G. Gallus,et al.  Pravastatin reduces carotid intima-media thickness progression in an asymptomatic hypercholesterolemic mediterranean population: the Carotid Atherosclerosis Italian Ultrasound Study. , 1996, The American journal of medicine.

[25]  P. Wolf,et al.  Current status of risk factors for stroke. , 1983, Neurologic clinics.

[26]  R. Westendorp,et al.  Stroke, statins, and cholesterol. A meta-analysis of randomized, placebo-controlled, double-blind trials with HMG-CoA reductase inhibitors. , 1997, Stroke.

[27]  J. Kjekshus,et al.  Effect of simvastatin on ischemic signs and symptoms in the Scandinavian simvastatin survival study (4S). , 1998, The American journal of cardiology.

[28]  C. J. Schwartz,et al.  Relationship Between Arterial Disease in Different Sites , 1962 .

[29]  R H Selzer,et al.  The Role of Carotid Arterial Intima-Media Thickness in Predicting Clinical Coronary Events , 1998, Annals of Internal Medicine.

[30]  W. Kannel,et al.  Lipoproteins, cardiovascular disease, and death. The Framingham study. , 1981, Archives of internal medicine.

[31]  C. Furberg,et al.  Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. , 1994, Circulation.

[32]  D. Kromhout.  Cholesterol, diastolic blood pressure, and stroke: 13 000 strokes in 450 000 people in 45 prospective cohorts , 1995, The Lancet.

[33]  G. Boysen,et al.  Influence of total cholesterol, high density lipoprotein cholesterol, and triglycerides on risk of cerebrovascular disease: the Copenhagen city heart study , 1994, BMJ.

[34]  Roger A. Renfrew,et al.  Lipid Research Clinics Program. , 1984, JAMA.

[35]  R. Rosenson,et al.  Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. , 1998, JAMA.

[36]  S. Kashyap,et al.  Correlation of the Extent and Severity of Atherosclerosis in the Coronary and Cerebral Arteries , 1963, Circulation.

[37]  C. Hennekens,et al.  Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. , 1997, JAMA.

[38]  G. Guyatt,et al.  Effect of HMGcoA reductase inhibitors on stroke. A meta-analysis of randomized, controlled trials. , 1998, Annals of internal medicine.

[39]  M. Pfeffer,et al.  Rationale and design of a secondary prevention trial of lowering normal plasma cholesterol levels after acute myocardial infarction: the Cholesterol and Recurrent Events trial (CARE) , 1991, The American journal of cardiology.

[40]  B. Davis,et al.  The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. , 1996, The New England journal of medicine.

[41]  D.,et al.  Regression Models and Life-Tables , 2022 .

[42]  David C. Atkins,et al.  Cholesterol Reduction and the Risk for Stroke in Men , 1993, Annals of Internal Medicine.

[43]  U. Tomiyasu,et al.  A Controlled Clinical Trial of a Diet High in Unsaturated Fat in Preventing Complications of Atherosclerosis , 1969 .

[44]  D. Jacobs,et al.  Serum cholesterol level and mortality findings for men screened in the multiple risk factor intervention trial , 1992 .